|
Name:
|
Vytorin
|
|
Generic:
|
Ezetimibe and Simvastatin
|
|
Manufacturer:
|
Merck/Schering-Plough
|
|
Date approved:
|
July 23, 2004
|
|
Status:
|
Prescription only
|
|
Approved uses:
|
Approved for the treatment of dyslipidemia, a disruption in the amount of lipids in the blood.
|
|
Off-Label uses:
|
Has a possible off-label ability to eliminate blood vessel inflammation often associated with being the cause of high BP
|
|
Side effects:
|
- Rhabdomyolysis - serious muscle damage linked to Simvastatin, an ingredient in Vytorin
- Myopathy - Muscle Toxicity
- Liver Damage
|
|
Related topics:
|
Zetia, Zocor, Unsafe Drugs, Simvastatin, Cholesterol
|
|
Common Misspellings:
|
Vitorin, Vitoran, vitoryn, vitoran, vyotrin
|
Vytorin, which is a combination of two drugs: ezetimibe (marketed as Zetia in the United States) and the statin drug simvastatin (marketed as Zocor). Vytorin is prescribed for the treatment of dyslipidemia, which occurs when the amount of lipids in the bloodstream is disrupted. In the U.S., this usually involves an elevation of lipids due to diet or lifestyle. The Zocor in Vytorin is designed to combat the disease by blocking an enzyme in the blood that enables the body's production of cholesterol, while the Zetia is meant to reduce the amount of cholesterol that the body absorbs from food.
However, an extensive study completed in mid 2006, and released in January 2008 has shown that taking Vytorin had no benefit on the buildup of artery plaque when compared with patients taking only Zocor. This finding is significant, as Vytorin is three times more expensive than the generic version of Zocor (simvastatin). The manufacturer has disputed the study's findings, but within weeks of the study's release a class action lawsuit has already been filed against Merck and Schering-Plough. The Vytorin lawsuit alleges that the companies have known since 2006 that their drug was no more effective than the cheaper generic Zocor, despite leading consumers to believe the opposite.
Merck Agrees to Pay $41.5 Million in Vytorin Class Action Lawsuit
Merck Agrees to pay $41.5 million in Vytorin Class Action Lawsuit. The makers of the popular cholesterol drugs, Vytorin and Zetia, have agreed to pay $41.5 million in a Vytorin class action lawsuit. Merck and Schering-Plough were accused of withholding unfavorable study results about the pharmaceutical blockbusters, Vytorin and Zetia, which showed that the drugs were not as effective at unclogging arteries as other less expensive alternatives.
read more
Three Studies Report Possible Vytorin-cancer Link
Three studies Report Possible Vytorin -cancer link. Three separate studies of the cholesterol-lowering combination drug Vytorin have reported results that show a possible connection between the drug and the development of cancer. Pedersen found that while the drug did not change the outcome of patients experiencing heart attacks, strokes, or surgeries related to the aortic valve in question, the number of cancer development cases in those taking Vytorin were greater than those patients taking the placebo.
read more
View the Vytorin Law Articles page here
Vytorin News Articles
Do most people fear side effects of prescriptions & would they prefer foods or supplements?
logowanie - esculap
View the
Vytorin News Articles
page here
Vytorin Newsfeeds
Merck, Schering Launch Huge Heart-Drug Test
Students Rally Together Against Legislation at State Capitol
View the
Vytorin Newsfeeds
page here
Vytorin Wikipedia
Ezetimibe/simvastatin
Ezetimibe
View the
Vytorin Wikipedia
page here